Search company, investor...

TetraLogic Pharmaceuticals

tetralogicpharma.com

Founded Year

2003

Stage

IPO | IPO

Total Raised

$115M

Date of IPO

12/12/2013

About TetraLogic Pharmaceuticals

TetraLogic Pharmaceuticals is focused on the discovery and development of drugs to treat cancer through technology which allows drugs to be developed that unblock the cell death or apoptosis pathway, resulting in the death of tumor cells. TetraLogic's lead Smac mimetic drug, birinapant (formerly TL32711), is entering Phase 2 clinical trials and is being developed for both solid tumors and hematological malignancies as a single agent and in combination with several standard-of-care cancer therapies.

Headquarters Location

343 Phoenixville Pike

Malvern, Pennsylvania, 19355,

United States

610-889-9900

Missing: TetraLogic Pharmaceuticals's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: TetraLogic Pharmaceuticals's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing TetraLogic Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

TetraLogic Pharmaceuticals is included in 1 Expert Collection, including Cancer.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

TetraLogic Pharmaceuticals Patents

TetraLogic Pharmaceuticals has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

6/25/2014

12/10/2019

Immunology, Clusters of differentiation, Immune system, HIV/AIDS, Hepatology

Grant

Application Date

6/25/2014

Grant Date

12/10/2019

Title

Related Topics

Immunology, Clusters of differentiation, Immune system, HIV/AIDS, Hepatology

Status

Grant

Latest TetraLogic Pharmaceuticals News

Medivir AB - Interim Report January - June 2021

Aug 19, 2021

Positive study results for MIV-818 and remetinostat. Design determined for the combination study with MIV-818 News provided by Share this article April – June Net turnover amounted to SEK 0.9 (4.0) million. The loss before interest, tax, depreciation and amortization (EBITDA) amounted to SEK -17.1 (-12.4) million. Basic and diluted earnings per share amounted to SEK -0.35 (-0.52) and SEK -0.35 (-0.52) respectively. Cash flow from operating activities amounted to SEK -21.9 (-23.3) million. Liquid assets and short-term investments at the end of the period amounted to SEK 247.8 (94.9) million. Significant events during the quarter On April 16, it was announced that Magnus Christensen had been appointed interim CEO of Medivir. He took up his new role in connection with Medivir's AGM on May 5, 2021. On April 19, it was announced that the overall results from the first part of the phase Ib study with MIV-818 were positive with a good safety and tolerability profile. Thus, the starting dose for the second part of the phase Ib study could be determined. In May, positive results from an investigator-initiated phase II clinical study of remetinostat in patients with squamous cell carcinoma (SCC) were released on clinicaltrials.gov. In May, the design for the upcoming phase 1b/2a combination study with the company's leading candidate drug, MIV-818 against liver cancer, was presented. In the study, MIV-818 will be administered in two combinations, with either lenvatinib, a tyrosine kinase inhibitor, or pembrolizumab, an anti-PD-1 checkpoint inhibitor. January - June Net turnover amounted to SEK 10.8 (11.4) million. The loss before interest, tax, depreciation and amortization (EBITDA) amounted to SEK -24.3 (-33.1) million. Basic and diluted earnings per share amounted to SEK -0.57 (-1.49) and SEK -0.57 (-1.49) respectively. Cash flow from operating activities amounted to SEK -23.3 (-40.0) million. Liquid assets and short-term investments at the end of the period amounted to SEK 247.8 (94.9) million. Significant events after the end of the period In July, Malene Jensen was appointed Vice President Clinical Development. She will assume her role on September 6, 2021. In August, it was announced that data from the MIV-818 phase 1b study will be presented at the ESMO Congress in September. In August, the positive results from the phase II study with remetinostat against basal cell carcinoma were published in the scientific journal Clinical Cancer Research. In August, it was announced that Medivir, through a renegotiated multi-party agreement, strengthens the business development potential for remetinostat. Conference call for investors, analysts and the media The Interim Report January - June 2021 will be presented by Medivir's interim CEO, Magnus Christensen. Time: Thursday, August 19, 2021, at 14.00 (CET). Phone numbers for participants from: Sweden + 46 8 505 583 55 Europe +44 33 3300 9271 US +1 646 722 4902 The conference call will also be streamed via a link on the website: www.medivir.com The presentation will be available on Medivir's website after completion of the conference. CEO's message The clinical development of MIV-818 remains in focus. Positive topline results in the phase 1b monotherapy study. The design determined for the phase 1b/2a combination study in the clinical MIV-818 program. Medivir's central task is to advance the clinical program for our leading candidate drug MIV-818, which has the potential to be a liver-directed, orally administered drug that can help patients with various cancers of the liver. This work has also characterized our operations also in the past quarter. In April we were able to announce that the results from the first part of the phase 1b study with MIV-818 were positive with a good safety and tolerability profile. Thereby, we were also able to determine the starting dose for the second part of the study, where we combine MIV-818 with standard treatment. Data from the first part of the phase 1b study will be presented at the ESMO scientific conference in September. Due to its unique mechanism of action, MIV-818 is attractive to combine with a multitude of other drugs for the treatment of hepatocellular carcinoma (HCC). We have been working on refining the design for the next step in the clinical program, the upcoming phase 1b/2a combination study with MIV-818, and at the end of May we presented how the study is structured. MIV-818 will be administered in two combinations, either with lenvatinib, a tyrosine kinase inhibitor, or with pembrolizumab, an anti-PD-1 checkpoint inhibitor. The study is an open-label, multi-center phase 1b/2a study that begins with a dose escalation part to determine the recommended phase 2 dose (RP2D). This is followed by the expansion study (phase 2a) with an initial evaluation of the safety and efficacy of the combinations of MIV-818 with lenvatinib or pembrolizumab. The study will include patients with HCC who have progressed on, or are intolerant of, first line standard therapy. We plan to recruit the first patient for the combination study in the second half of 2021. However, we cannot guarantee that the Covid-19 pandemic will not affect our schedule. MIV-818 is proprietary and wholly owned by Medivir, i.e. we do not have to pay any future milestones or royalties to any third party. We have two more drug development projects in the clinical development phase, remetinostat, and MIV-711. Medivir does not conduct clinical development of these projects on its own, but instead seeks partners for further development. During the quarter, positive results were published from an investigator-initiated clinical phase II study of remetinostat in patients with squamous cell carcinoma (SCC). The study was conducted at the Stanford University School of Medicine in California, USA. The primary objective of the study was to assess the effects of topical remetinostat on biopsy-proven SCC and SCC in situ tumors. In August, the positive results from the phase II study with remetinostat in patients with BCC were also published in the scientific journal Clinical Cancer Research. The results are very promising and provide further support for the potential of remetinostat as a treatment for a number of skin-associated cancers in addition to cutaneous T-cell lymphoma (CTCL). Medivir renegotiated in August a multi-party agreement with the originators of remetinostat and TetraLogic Pharmaceuticals Corporation and The Leukemia & Lymphoma Society regarding the financial obligations for remetinostat in order to create better conditions for business development. Medivir's birinapant project, for the treatment of solid tumors, was outlicensed to the American company IGM Biosciences at the beginning of the year. IGM has the global and exclusive rights to develop birinapant. According to IGM's Q2 report, they plan to initiate clinical trials with birinapant in combination with their proprietary antibody IGM-8444 during 2021. At Medivir's AGM on May 5, former CEO Yilmaz Mahshid was elected new board member and Uli Hacksell was elected chairman of the board. This guarantee continued scientific vitality and business acumen in the Board's work. In July, Malene Jensen was recruited as Vice President Clinical Development and a member of the company's management team. With extensive experience in clinical development, Malene will focus on the clinical studies with MIV-818. I am really impressed by the determination and dedication shared by all Medivir employees. The goal is to develop an effective drug against liver cancer through MIV-818. Given that this work continues to show good results, it could make a big difference for patients and for healthcare and thus also for the company's shareholders. Magnus Christensen

TetraLogic Pharmaceuticals Frequently Asked Questions (FAQ)

  • When was TetraLogic Pharmaceuticals founded?

    TetraLogic Pharmaceuticals was founded in 2003.

  • Where is TetraLogic Pharmaceuticals's headquarters?

    TetraLogic Pharmaceuticals's headquarters is located at 343 Phoenixville Pike, Malvern.

  • What is TetraLogic Pharmaceuticals's latest funding round?

    TetraLogic Pharmaceuticals's latest funding round is IPO.

  • How much did TetraLogic Pharmaceuticals raise?

    TetraLogic Pharmaceuticals raised a total of $115M.

  • Who are the investors of TetraLogic Pharmaceuticals?

    Investors of TetraLogic Pharmaceuticals include Novitas Capital, Quaker BioVentures, Latterell Venture Partners, Hatteras Venture Partners, Clarus and 7 more.

  • Who are TetraLogic Pharmaceuticals's competitors?

    Competitors of TetraLogic Pharmaceuticals include Array Biopharma, OncoMed Pharmaceuticals, Keryx Biopharmaceuticals, Helomics, Biosceptre International, Athenex, Ambit Biosciences, EpiCept, Nanomed Pharmaceuticals, Gemin X and 13 more.

Compare TetraLogic Pharmaceuticals to Competitors

E
Epeius Biotechnologies

Scientists at Epeius Biotechnologies have developed a targeted delivery system (TDS) that can transport genes or other therapeutic agents directly to diseased areas in the body. This pathotropic, or disease-seeking, technology has enabled the company to develop Rexin-G, a tumor-targeted, injectable gene delivery system that has demonstrated remarkable safety and single-agent efficacy in clinical trials internationally. Rexin-G is currently in clinical trials for pancreatic cancer in the U.S. ƒƒ‚ƒš‚" where it has achieved FDA orphan drug status ƒƒ‚ƒš‚" and has accelerated approval in the Philippines for the treatment of all solid tumors that are resistant to standard chemotherapy. The company's international clinical outreach with Rexin-G has enabled us to expedite further demonstrations that Rexin-G is highly active in a broad spectrum of chemo-resistant tumor types with efficacy and excellent safety profiles. The company are a biopharmaceutical company focused on expanding the therapeutic utility and commercialization of the company's pathotropic approach to disease treatment through internal development and commercialization of the company's oncology products and cancer vaccines, and through strategic partnerships in additional areas of oncology, immunology, cardiovascular, ocular, and wound healing applications, precision targeted diagnostics, and stem cell technologies.

A
Adriacell

Adriacell s.r.l is a biotech company focused in oncology pharmaceuticals founded in Basovizza (Trieste) in March 2004 by Prof. Christian Kuehne, an Austrian citizen.nThe company is leveraging its efforts and scientific expertise to successfully solve important worldwide health problems; in particular, it has been striving to develop a new class of anti-tumour therapeutics and to create a series of powerful diagnostics for the early detection of cancer progression. The company is also developing new and highly powerful delivery solutions through small molecules as the basis for a new class of anti-infective drugs.nAdriaCell owns a patented system that can be used for the study of events subsequent to DNA double strand breaks, a very important issue for cancer research and diagnostics. Adriacell is currently evaluating a new class of therapeutics for cancer; its main lead compound is about to enter the pharmacokinetic and toxicology phases.nAdriacell Vision is to become a leader biotech drug development company concentrated in the development of solutions (treatment and diagnostics) for tumours characterized by low probability of survival for patients and of anti infective agents. Thanks to future developments in research and test activities Adriacell solutions will hopefully become useful in a wider range of pathologies.

O
Onyvax

Onyvax is developing new cancer therapies that harness the selective power of the immune system to seek out and destroy tumor cells. Onyvax's products specifically target cancer cells, increasing the likelihood that they will be effective while minimising side effects associated with many conventional treatments. These therapies can broadly be classed as therapeutic cancer vaccines. Onyvax's lead product is in clinical trials for the treatment of prostate cancer and is poised to enter the final stages of development. Onyvax is committed to the commercialisation of therapies that enhance survival while maintaining a high quality of life for patients. The Company is based in London and has collaborations with leading hospitals and other institutions throughout Europe and the US.

O
Orca Therapeutics

Central to ORCA Therapeutics is the use of Oncolytic Replication Competent Agents (ORCA). These agents are typically derived from naturally occurring oncolytic viruses. Oncolytic viruses replicate selectively in cancer cells and kill these cells during replication. Upon destroying the infected cancer cells, progeny viruses are released that in turn will infect and kill adjacent cancer cells. A strongly enhanced anti-cancer effect is the result. In addition, oncolytic viruses can be used as efficient delivery agents - e.g. to express anti-cancer products at high levels in cancer cells- or as anti-cancer vaccines.

M
Marillion Pharmaceuticals

Marillion Pharmaceuticals, Inc. - Marillion is developing clinical-stage drugs in oncology and oncology supportive care. 177Lu-AMBA is a targeted radiotherapeutic, with the low level radiation of lutetium that aims to utilize an receptor-based technology, and can serve as both a diagnostic and therapeutic agent. The targeting capability means that 177Lu-AMBA homes in on tumor cells and spares normal tissues. 177Lu-AMBA is being pursued initially to treat hormone-resistant prostate cancer, has been studied in a phase I trial in Europe. Marillion also is developing PilobucTM , buccal formulation of pilocarpine ,for the treatment of dry mouth, shown in clinical trials to effectively and conveniently deliver the drug with reduced side effects compared to other routes of administration.PilobucTM buccal formulation of pilocarpine has the potential to be a product in the xerostomia market. Marillion is preparing for phase II trials of the product candidate..

P
Psimei Pharmaceutical

Psimei Pharmaceuticals is developing boron-based drugs for applications in Photon Activation Therapy (PAT). This involves the use of standard radiotherapy to activate boron-based compounds which selectively target solid tumours. This results in an amplification of the therapeutic effect of conventional radiotherapy. Pre-clinical data for Psimei's lead product, PP200PAT, has demonstrated 90% true cure rates at 6 months in tumour models compared with 30% for conventional radiotherapy alone. It also enabled much shorter treatment regimes - days as opposed to weeks. This drug is being prepared for clinical development.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.